Difference in Rill Costs With INA-CBGs Rates and Treatment Rationality of
\nInpatient Asthma Children

Asthma in children may affect children's efficiency at school because frequent attacks occur which
\ndisrupt children's activities, so that asthma in children is a serious problem that requires appropriate
\ntreatment. The aim was to know the difference in real costs and INA-CBGs rates and to analyze Drug-
\nRelated Problems (DRP) based on the severity of asthma and the real costs for childhood asthma at
\nAnwar Medika Sidoarjo Hospital. The design of this study was retrospective using patient medical
\nrecord data collection, for January 2020-December 2022. Data collection containing real cost data and
\nBPJS claim cost data. Analysis of DRP based on PCNE (Pharmaceutical Care Network Europe) includes
\nproblems and causes. There were 77 subjects. the real costs for the severity of mild asthma class I, class
\nIII, and moderate asthma class II were high when compared with the INA-CBGS rates, while the severity
\nlevel of severe asthma class III it was found that the real costs were lower than the INA-CBGS rates.
\nThere is no difference between total real costs and INA-CBGS rates for asthma cases in BPJS
\nparticipating children. The average real cost is Rp. 2,557,453 and the average INA-CBGs tariff is Rp.
\n2,792,873. There was no significant difference between real costs and INA-CBGS rates (P=0.162). All
\nrespondents experienced DRP (100%) and the highest incidence of DRP was M3.1 and P1.2 in 44
\npeople (57.14%) with 180 cases (60.82%). In 77 patients with a total number of cases of 296, the real
\ncosts were mostly incurred in class III mild asthma patients (58 people), namely DRP type M3.1 with
\nP1.2 with an average cost of Rp. 2,640,221.